Lyell Immunopharma (LYEL) Change in Accured Expenses (2020 - 2026)

Lyell Immunopharma has reported Change in Accured Expenses for 7 years, with the latest figure at -$3.6 million in Q1 2026.

• Quarterly Change in Accured Expenses rose 63.56% year-over-year to -$3.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.4 million (up 80.88% YoY) and the FY2025 annual result came in at -$7.6 million, down 511.36% from the prior year.
• Change in Accured Expenses fell to -$3.6 million in Q1 2026 per LYEL's latest filing, from $4.9 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $5.4 million in Q4 2022 and troughed at -$9.8 million in Q1 2025.
• A 5-year average of -$802411.8 and a median of -$766000.0 in 2022 frame the typical range for Change in Accured Expenses.
• The widest YoY moves for Change in Accured Expenses: up 491.07% in 2025, down 745.35% in 2025.
• Over 5 years, Change in Accured Expenses stood at $5.4 million in 2022, then tumbled by 132.37% to -$1.7 million in 2023, then increased by 27.89% to -$1.3 million in 2024, then jumped by 491.07% to $4.9 million in 2025, then slumped by 172.74% to -$3.6 million in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered -$3.6 million, $4.9 million, and $572000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.